Cannabis Hyperemesis Syndrome: the paradoxical picture

TL;DR

• Cyclic, often severe nausea and vomiting in chronic cannabis users.
• Classic sign: symptom relief from hot showers or baths.
• Clinical diagnosis (Sorensen 2017 criteria), no specific lab marker.
• Only durable therapy: complete cannabis abstinence. Acute: haloperidol or topical capsaicin.

Why cannabis of all things?

Chronic receptor down-regulation and TRPV1 dysregulation (TRPV1 also reacts to heat) explain the paradox: the same molecule that is acutely antiemetic becomes pro-emetic after years of exposure.

Treatment

Acute: rehydration, haloperidol 0.5-1 mg IV often outperforms ondansetron; topical capsaicin cream 0.025-0.1 % on abdomen. Long-term: abstinence. Recurrence is only prevented by lasting cessation.

Pathophysiological mechanisms and differential diagnosis

The development of the syndrome is closely linked to the biphasic effect of cannabinoids. While low doses have an antiemetic effect via central receptors, chronic overstimulation during intensive use leads to an accumulation of the active substances in adipose tissue. This promotes dysregulation of the receptors in the gastrointestinal tract, which delays gastric emptying and disrupts intestinal motility. These local effects ultimately override the actually dampening effect in the brain and trigger the characteristic, severe vomiting attacks.

The clinical distinction between this syndrome and cyclic vomiting unrelated to cannabis poses diagnostic challenges for professionals. Since no specific laboratory parameters exist, diagnosis is primarily made by excluding other gastrointestinal diseases such as pancreatitis or cholecystitis. The conspicuous behavior of seeking relief through very warm water, as well as the complete resolution of symptoms after cessation of use, are the most reliable indicators for a correct differentiation in daily clinical practice.

• Biphasic effect: The typically antiemetic effect reverses into its opposite when the system is chronically overloaded.
• Delayed gastric emptying: Local receptor disruptions in the digestive tract dominate over central control in the brain.
• Diagnosis of exclusion: The necessity of systematically ruling out organic causes in the gastrointestinal tract before establishing a diagnosis.
• Diagnostic key: The characteristic showering behavior and improvement upon abstinence confirm the diagnosis.

Swiss context, healthcare reality and contact points

In Switzerland, emergency departments are recording an increasing number of patients with the typical symptoms of this syndrome. Medical staff are increasingly sensitised to specifically ask about consumption habits in cases of unexplained, cyclical vomiting. Close monitoring is also recommended in the context of medical cannabis therapies, which have been prescribable by doctors without an exceptional permit from the BAG since August 2022, in order to detect early signs of intolerance or overdose in the gastrointestinal tract in a timely manner.

In case of suspected acute poisoning or severe symptoms, the national emergency number of Tox Info Suisse on 145 serves as the first competent point of contact for those affected and their relatives. Since long-term management of the syndrome requires complete abstinence, Swiss hospitals work closely with regional addiction counselling centres. This interdisciplinary aftercare supports those affected in permanently stopping consumption, thereby effectively preventing a recurrence of the painful episodes.

• Sensitisation in emergency care: Swiss hospitals are increasingly training their staff to recognise this specific clinical picture.
• Tox Info Suisse: The emergency number 145 offers round-the-clock initial professional assessments in cases of severe vomiting attacks.
• Medical cannabis in focus: Even with legally prescribed therapies, close monitoring of gastrointestinal function is advisable.
• Interdisciplinary aftercare: Cooperation between acute medicine and addiction counselling ensures the long-term success of abstinence.

Clinical phases and long-term management

The course of the syndrome can be clinically divided into three phases: the prodromal phase, the hyperemetic phase, and the recovery phase. In the prodromal phase, which often lasts for months, those affected usually complain of morning nausea and mild abdominal pain, but frequently continue to consume cannabis in the belief that this will alleviate the symptoms. This accelerates the transition to the hyperemetic phase, which is characterised by uncontrollable vomiting, dehydration, and pronounced weight loss, and usually requires hospitalisation.

The recovery phase only begins after consistent abstinence from all cannabinoid-containing products. The regeneration of receptors in the digestive system takes time, which is why close medical supervision in the first few weeks after stopping consumption is crucial. Since even small amounts of cannabinoids can trigger an immediate relapse into the acute phase of the illness, psychotherapeutic support to consolidate abstinence is at the core of the long-term treatment plan.

• Prodromal phase: Early warning signs such as morning nausea are often mistakenly treated by those affected with increased consumption.
• Hyperemetic phase: Acute crisis phase with severe vomiting, requiring rapid medical intervention.
• Recovery phase: The gradual normalisation of bodily functions only begins after complete cessation of consumption.
• Risk of relapse: Even minimal renewed consumption can reactivate the entire range of symptoms within a very short time.

FAQ